Logo-jre
Submitted: 21 Aug 2022
Accepted: 02 Oct 2022
ePublished: 15 Oct 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Endocrinol. 2022;8: e19064.
doi: 10.34172/jre.2022.19064
  Abstract View: 67
  PDF Download: 54

Original Article

Effect of nanocurcumin on serum levels of betatrophin and irisin in patients with metabolic syndrome; a clinical trial

Hamid Gholami 1 ORCID logo, Nejat Kheiripour 2 ORCID logo, Mehdi Bahmani 3 ORCID logo, Akram Ranjbar 4 ORCID logo, Zahra Khodamoradi 5 ORCID logo, Shiva Borzouei 6* ORCID logo

1 Lorestan University of Medical Sciences, Khoram-Abad, Iran.
2 Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.
3 Department of Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
4 Toxicology and Pharmacology Department, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.
5 Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran.
6 Clinical Research Development Unit of Shahid Beheshti Hospital, Hamadan University of Medical science, Hamadan, Iran.
*Corresponding Author: Corresponding Author: Shiva Borzouei, Email: borzooeishiva@yahoo.com, , Email: Borzouei@umsha.ac.ir

Abstract

Introduction: Metabolic syndrome is a highly prevalent disease with combination of cardio metabolic risk factors. Insulin resistance is the most important reason of metabolic syndrome.

Objectives: The study aimed to evaluate the effects of nanocurcumin on insulin resistance and serum level irisin and betatrophin in patients with metabolic syndrome.

Patients and Methods: Sixty metabolic syndrome patients (30 males and 30 females) received 80 mg/daily nanocurcumin for three months. The samples of fasting blood were collected at the beginning of the study and after 90-days intervention to measure the biomarkers.

Results: comparing pre and post treatment with nanocurcumin values revealed a significant change in fasting plasma glucose (FPG), fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and irisin (P>0.05), but there was no change in the amount of betatrophin (P>0.05).

Conclusion: According to the results, it seems that the use of nanocurcumin for 90 days may have positive effects on some metabolic components. However, more studies with larger sample sizes are needed to confirm the findings. Trial registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT20120215009014N214; https:// www.irct.ir/trial/30187, ethical code; IR.UMSHA.REC.1396.859).


Citation: Gholami H, Kheiripour N, Bahmani M, Ranjbar A, Khodamoradi Z, Borzouei S. Effect of nanocurcumin on serum levels of betatrophin and irisin in patients with metabolic syndrome; a clinical trial. J Ren Endocrinol. 2022;8:e19064. doi: 10.34172/jre.2022.19064.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 68

Your browser does not support the canvas element.


PDF Download: 54

Your browser does not support the canvas element.